Q2 2026 13F · SEC CIK 1807489
M28 Capital Management LP
Hedge fundFiled 2026-08-13 for Q2 2026. Open the filing ↗ · All SEC filings ↗
- Reported 13F value
- $47.2M
- Reported positions
- 9
- Top holdings a year, 3 yrs
- -12.4%
- Average holding period
- 4.6 yrs
M28 Capital Management LP is a hedge fund that reported 9 positions worth $47.2M in its Q2 2026 13F, filed 2026-08-13. Its largest holdings were Wave Life Sciences Ltd (WVE, 56.5%), Invivyd Inc (IVVD, 17.1%), TG Therapeutics Inc (TGTX, 10.3%). A portfolio copying its top holdings returned -12.4% a year over the last 3 years, against 20.4% for the S&P 500.
M28 Capital Management LP holdings all 9 positions.
Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.
| Stock | % of 13F value | Share change | Reported value |
|---|---|---|---|
| WVEWave Life Sciences Ltd | 56.5% | +0.0% | $26.7M |
| IVVDInvivyd Inc | 17.1% | +0.0% | $8.1M |
| TGTXTG Therapeutics Inc | 10.3% | +0.0% | $4.9M |
| ARWRArrowhead Pharmaceuticals in | 6.4% | +0.0% | $3.0M |
| GUTSFractyl Health Inc | 3.1% | +0.0% | $1.5M |
| PRQRProqr Thrapeutics N V | 2.4% | +0.0% | $1.1M |
| SLNSilence Therapeutics PLC | 2.4% | +0.0% | $1.1M |
| RCKTRocket Pharmaceuticals Inc | 1.5% | +0.0% | $721K |
| CRISCuris Inc | 0.3% | +0.0% | $149K |
What M28 Capital Management LP bought and sold in Q2 2026, against Q1 2026.
New positions
No new positions among the largest holdings.
Added to
No position grew by more than 5%.
Reduced
No position shrank by more than 5%.
Sold out
Nothing sold out.
Share counts compared with the Q1 2026 13F; a split also changes share counts.
How the holdings did against the S&P 500.
- 1 year
- -34.3% /yr
- S&P 500 +20.1%
- 3 years
- -12.4% /yr
- S&P 500 +20.4%
- 5 years
- -18.9% /yr
- S&P 500 +13.0%
A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.
Reported 13F value by quarter.
| Quarter | 13F value | Positions |
|---|---|---|
| Q2 2026 | $47.2M | 9 |
| Q1 2026 | $53.8M | 9 |
| Q4 2025 | $137.6M | 9 |
| Q3 2025 | $68.0M | 9 |
| Q2 2025 | $58.6M | 9 |
| Q1 2025 | $73.0M | 11 |
| Q4 2024 | $101.9M | 11 |
| Q3 2024 | $91.0M | 11 |
| Q2 2024 | $77.1M | 11 |
| Q1 2024 | $135.3M | 11 |
| Q4 2023 | $120.7M | 10 |
| Q3 2023 | $87.2M | 11 |
Questions about M28 Capital Management LP's portfolio
What stocks does M28 Capital Management LP own?
M28 Capital Management LP's latest 13F, for Q2 2026 and filed Aug 13, 2026, lists 9 positions worth $47.2M. The largest are Wave Life Sciences Ltd (WVE) at 56.5%, Invivyd Inc (IVVD) at 17.1%, TG Therapeutics Inc (TGTX) at 10.3%, Arrowhead Pharmaceuticals in (ARWR) at 6.4% and Fractyl Health Inc (GUTS) at 3.1%.
What did M28 Capital Management LP buy last quarter?
M28 Capital Management LP opened no new positions and grew none by more than 5% among its largest holdings in Q2 2026.
What did M28 Capital Management LP sell last quarter?
M28 Capital Management LP sold out of nothing and cut no large position by more than 5% in Q2 2026.
How has M28 Capital Management LP's portfolio performed?
A portfolio copying M28 Capital Management LP's 20 largest 13F holdings each quarter, from the day each filing was public, returned -12.4% a year over the last 3 years, against +20.4% for the S&P 500. Over 1 year: -34.3% against +20.1%. Over 5 years: -18.9% a year against +13.0%.
When is M28 Capital Management LP's next 13F filing due?
13F filings are due 45 days after each quarter ends. M28 Capital Management LP's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.